Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital. Preliminary PET imaging data from the study show encouraging signals in acute MS lesions, offering a potential breakthrough in how myelin damage is assessed. The novel imaging technique is designed to distinguish demyelinated nerve fibers that may still be viable from those that have suffered permanent damage, which could provide a more precise method for measuring myelin loss and repair in patients.
This advancement is directly relevant to Lucid-MS, the company’s investigational compound aimed at inhibiting demyelination by targeting the enzyme PAD2, implicated in myelin degradation. The combination of a more accurate imaging tool and a drug candidate that addresses the underlying cause of MS presents a compelling approach to treatment. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions, according to a recent article.
The study’s progress is a critical step for Quantum BioPharma as it seeks to validate its imaging biomarker and potentially accelerate the development of Lucid-MS. With MS affecting millions worldwide, the ability to differentiate between reversible and irreversible nerve damage could transform patient monitoring and drug efficacy assessment. The preliminary results, while early, hint at the potential for more personalized treatment strategies in MS.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on the research and development of Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of MS.
In addition to its MS program, Quantum BioPharma has spun out its OTC product unbuzzd to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, and royalty payments of 7% of sales until reaching $250 million, after which the royalty drops to 3% in perpetuity. The company retains full rights to develop pharmaceutical and medical uses of similar products.
For more information on Quantum BioPharma and its latest news, visit the company’s newsroom at https://nnw.fm/QNTM. The full article discussing these developments can be accessed at https://nnw.fm/fsDHa.
